#Public health

Today announced the initiation of the randomized Stage 3 trial of ponatinib.

Trial Design and Statistical Analysis The EPIC trial can be a randomized, two-arm, multicenter trial that compares the efficacy of ponatinib with that of imatinib in adult sufferers with diagnosed CML in the chronic phase newly. The trial will end up being conducted at up to 175 investigational sites in North America, Europe and Asia-Pacific. Sufferers in the trial should be at least 18 years of age and identified as having CML within six months prior to enrollment. Approximately 500 patients will be randomized 1:1 to standard doses of ponatinib or imatinib . Escalation of the imatinib dose to 600 mg or 800 mg per day is permitted.In March 2014, a guideline was released by the AAN on complementary alternative therapies, such as medical marijuana, to take care of multiple sclerosis . In 2014 April, the AAN released a systematic review on the efficacy and protection of medical marijuana in chosen brain and nervous system disorders, such as epilepsy, Parkinson's disease, Tourette and MS syndrome. The position statement also notes that many cannabis preparations found in studies are not available in the United States. ‘It isn’t suitable to extrapolate the outcomes of trials of standardized preparations to various other, non-standardized, non-regulated cannabis products that may be commercially obtainable in states with laws supporting the usage of medical marijuana,’ Patel said.

ABI Research study shows global marketplace for medical robotics to attain almost $1.3 billion in 2016 Robotic technology has been used to supply medical care about a limited basis over the past two decades, helping to make surgical procedures and physical rehabilitation more efficient and effective, and safer for individuals.